Cargando…

Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs

Background: The biologic disease-modifying antirheumatic drugs (bDMARDs) are currently incorporated as part of the pharmacotherapy management of inflammatory arthritis (IA). Adherence to bDMARDs is crucial to ensure treatment success in IA. However, most of the recent studies evaluated adherence lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdul Razak, Salmi, Makmor Bakry, Mohd, Mohamed Said, Mohd Shahrir, Tan, Chai-Eng, Md Redzuan, Adyani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681069/ https://www.ncbi.nlm.nih.gov/pubmed/33240088 http://dx.doi.org/10.3389/fphar.2020.572260

Ejemplares similares

Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence
por: Chong, Chia Chee, et al.
Publicado: (2021)

Drug-Related Problems in Pulmonary Hypertension with Valvular Heart Disease
por: Abdul-Ghaffar, Farizan, et al.
Publicado: (2022)

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
por: Lee, Fei Yee, et al.
Publicado: (2022)

Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study
por: Lee, Fei Yee, et al.
Publicado: (2021)

How payment scheme affects patients’ adherence to medications? A systematic review
por: Aziz, Hamiza, et al.
Publicado: (2016)

Adherence to preventive medications in asthmatic children at a tertiary care teaching hospital in Malaysia
por: Md Redzuan, Adyani, et al.
Publicado: (2014)

Qualitative exploration of the modifiable factors for medication adherence among subsidised and self-paying patients in Malaysia
por: Aziz, Hamiza, et al.
Publicado: (2018)

Factors associated with lipid goal attainment among acute coronary syndrome patients
por: Mohd-Zulkefli, Siti-Zainora, et al.
Publicado: (2016)

Impact of complementary and alternative medicines on antiepileptic medication adherence among epilepsy patients
por: Farrukh, Muhammad Junaid, et al.
Publicado: (2021)

Medication adherence status among patients with neurological conditions and its association with quality of life
por: Junaid Farrukh, Muhammad, et al.
Publicado: (2021)

Use of complementary and alternative medicine and adherence to antiepileptic drug therapy among epilepsy patients: a systematic review
por: Farrukh, Muhammad Junaid, et al.
Publicado: (2018)

Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study
por: Butt, Mubashra, et al.
Publicado: (2016)

Exploring Culture, Religiosity and Spirituality Influence on Antihypertensive Medication Adherence Among Specialised Population: A Qualitative Ethnographic Approach
por: Abdul Wahab, Noor Azizah, et al.
Publicado: (2021)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance
por: Mohd Tahir, Nor Asyikin, et al.
Publicado: (2020)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Use of Complementary and Alternative Medicine and Adherence to Medication Therapy Among Stroke Patients: A Meta-analysis and Systematic Review
por: Rajahthurai, Sareneya Dashni, et al.
Publicado: (2022)

Pathogenesis of Epilepsy: Challenges in Animal Models
por: Hui Yin, Yow, et al.
Publicado: (2013)

Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector
por: Ahmad, Nur Sufiza, et al.
Publicado: (2019)

Multi stakeholders of health and industries perspectives on medicine price transparency initiative in private health care settings in Malaysia
por: Sufiza Ahmad, Nur, et al.
Publicado: (2020)

Impact of COVID-19 pandemic on STEMI thrombolysis and Emergency Department's performance in a non-PCI capable tertiary hospital
por: Koh, Hock Peng, et al.
Publicado: (2022)

Mortality outcomes and predictors of failed thrombolysis following STEMI thrombolysis in a non-PCI capable tertiary hospital: a 5-year analysis
por: Koh, Hock Peng, et al.
Publicado: (2023)

Patient-centered education in dyslipidemia management: a systematic review
por: Ismail, Farhana Fakhira, et al.
Publicado: (2023)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
por: Czekalska, Anna, et al.
Publicado: (2019)

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
por: Best, Jennie H., et al.
Publicado: (2020)

A clinical tool to predict Plasmodium vivax recurrence in Malaysia
por: Mat Ariffin, Norliza, et al.
Publicado: (2017)

Publics’ Knowledge, Perception and Practice on Management of Minor Ailment in Community Pharmacy in Malaysia
por: Tew, Mei Mei, et al.
Publicado: (2023)

Upper Respiratory Tract Symptoms, Renal Involvement and Vasculitis: A Case Report and Review of Wegener Granulomatosis
por: Said, Mohd Shahrir Mohamed
Publicado: (2010)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
por: Kaló, Zoltán, et al.
Publicado: (2017)

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
por: Góralczyk, Alicja, et al.
Publicado: (2020)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Factors Affecting Primaquine Combination Treatment in Malaria Patients in Selangor, Malaysia
por: Ariffin, Norliza Mat, et al.
Publicado: (2017)

Consumers' Knowledge, Attitudes, and Practices Toward Medicine Price Transparency at Private Healthcare Setting in Malaysia
por: Ahmad, Nur Sufiza, et al.
Publicado: (2021)

Prevalence and predictive factors of tuberculosis treatment interruption in the Asia region: a systematic review and meta-analysis
por: Oh, Ai Ling, et al.
Publicado: (2023)

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence
por: van Heuckelum, M., et al.
Publicado: (2019)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
por: Daïen, Claire I., et al.
Publicado: (2014)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kckk0gdsf1ankuc5jivglo0hj7